PeerCurrent.com|Stay current with the people and research shaping what comes next.

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Researcher

Yong Xu

Sichuan University

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs1 Trials Reviews1 Guidelines

Latest

Everything in the corpus, newest first.

SEP 3, 2026 · REVIEW

Sodium-glucose cotransporter-2 inhibitors and gastrointestinal neoplasm risk in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials

Clinical and Experimental Medicine

A rigorous meta-analysis of 48 RCTs with 48,765 participants showing no significant association between SGLT2 inhibitors and gastrointestinal neoplasm risk, with consistent null findings across multiple site-specific and subgroup analyses, though long-term safety remains incompletely characterized.

Strong EvidenceJiajie Xie Qi Wu Metabolism, Diabetes, and Cancer

Reported

Overall GI neoplasm risk, odds ra…1.10

Overall GI neoplasm risk, 95% CI0.84–1.44

Overall GI neoplasm risk, p-value0.46

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support